Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.


Options:
A: Arm Label: Dapagliflozin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Placebo for saxagliptin, Drug: Placebo for glimepiride | Arm Label: Dapagliflozin+saxagliptin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Saxagliptin, Drug: Placebo for glimepiride | Arm Label: Glimepiride+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo for dapagliflozin, Drug: Placebo for saxagliptin | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for dapagliflozin; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for saxagliptin; Assigned to Arm(s): Dapagliflozin+metformin, Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for glimepiride; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin
B: Intervention Type: DRUG; Name: muraglitazar; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
D: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin, Drug: Sulphonylruea | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Sulphonylruea; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo

Answer: D